Navigation Links
Uroplasty Appoints Brett Reynolds As Chief Financial Officer
Date:8/12/2013

MINNEAPOLIS, Aug. 12, 2013 /PRNewswire/ -- Uroplasty, Inc. (NASDAQ: UPI), a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions, today announced the appointment of Brett A. Reynolds as Senior Vice President and Chief Financial Officer. He joins Uroplasty following 10 years in senior positions, including Chief Financial Officer, with Synovis Life Technologies, a Twin Cities based medical device manufacturer acquired by Baxter International last year. 

"Brett's significant industry operational experience and proven public company financial leadership will be a valuable asset to Uroplasty.  His track record of building strong financial organizations and processes expands the depth of our executive leadership team and we are delighted to have him on board in this key role," said Rob Kill, President & CEO of Uroplasty.

Mr. Reynolds experience spans more than 20 years in finance and operations.  He was most recently the CFO of Synovis, staying on with the company as Site Leader following its sale to Baxter International in February 2012 for $325 million. Prior to Synovis, Mr. Reynolds served in executive financial positions at Chiquita Processed Foods, Arthur Andersen and Deloitte & Touche.

Mr. Reynolds is a Certified Public Accountant and holds a BA in Accounting and an MBA from the University of Minnesota's Carlson School of Management.

About Uroplasty, Inc.

Uroplasty, Inc., headquartered in Minnetonka, Minnesota, with wholly-owned subsidiaries in The Netherlands and the United Kingdom is a global medical company committed to offering transformative treatment options to specialty physicians.  Our products are designed to help providers change the lives of their voiding dysfunction patients and strengthen the efficiency of their practices. Our focus is the continued commercialization of our Urgent® PC Neuromodulation System, the only FDA-cleared system that delivers percutaneous tibial nerve stimulation (PTNS) for the office-based treatment of overactive bladder and associated symptoms of urgency, frequency and urge incontinence. We also offer Macroplastique®, an injectable urethral bulking agent for the treatment of adult female stress urinary incontinence primarily due to intrinsic sphincter deficiency. For more information on the company and its products, please visit Uroplasty, Inc. at www.uroplasty.com.

Forward-Looking Information
This press release contains forward-looking statements that reflect our best estimates regarding future events and financial performance.  These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from our anticipated results.  We discuss in detail the factors that may affect the achievement of our forward-looking statements in our Annual Report on Form 10-K filed with the SEC.

For Further Information:
Uroplasty, Inc.
Rob Kill, President and CEO
952.426.6151

EVC Group
Jenifer Kirtland (Investors)/Janine McCargo (Business Media)
415.568.9349/646.688.0245


'/>"/>
SOURCE Uroplasty, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Uroplasty to Present at the 11th Annual JMP Securities Research Conference
2. Uroplasty Announces Product Development and New Clinical Trial Initiatives
3. Uroplasty Reports Fiscal Fourth Quarter And Full Year 2012 Financial Results
4. Uroplasty To Present At The JMP Securities Healthcare Conference
5. Uroplasty to Issue First Quarter of Fiscal 2013 Financial Results on July 26, 2012
6. Uroplasty Reports Fiscal First Quarter 2013 Financial Results
7. Uroplasty To Participate In Two Upcoming Conferences
8. Uroplasty Reports Fiscal Second Quarter 2013 Financial Results
9. Uroplasty To Participate In Two Upcoming Investor Conferences
10. Uroplasty To Participate In The Oppenheimer 23rd Annual Healthcare Conference
11. Uroplasty Reports Fiscal Third Quarter 2013 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... June 23, 2016 Roche (SIX: RO, ROG; ... for its Elecsys BRAHMS PCT (procalcitonin) assay as a ... septic shock. With this clearance, Roche is the first ... integrated solution for sepsis risk assessment and management. ... infection and PCT levels in blood can aid clinicians ...
(Date:6/23/2016)... Capricor Therapeutics, Inc. ... company focused on the discovery, development and commercialization ... in its ongoing randomized HOPE-Duchenne clinical trial (Halt ... its 24-patient target. Capricor expects the trial to ... 2016, and to report top line data from ...
(Date:6/23/2016)... -- Bracket , a leading clinical trial technology and ... platform, Bracket eCOA (SM) 6.0, at the 52 nd ... 2016 in Philadelphia , Pennsylvania.  A demonstration ... of its kind to fully integrate with RTSM, will be ... is a flexible platform for electronic clinical outcomes assessments that ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... 2016 , ... Quality metrics are proliferating in cancer care, and are derived ... eye of the beholder, according to experts who offered insights and commentary in the ... Care. For the full issue, click here . , For the American Society ...
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements ... was developed to enhance the health of felines. The formula is all-natural and is ... herbs in the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus ...
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the American ... Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. ... including advance care planning, healthcare costs and patient and family engagement. , AIR ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture ... said Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package ... Final Cut Pro X . Simply select a ProHand generator and drag it ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... recover from injury. Recently, he has implemented orthobiologic procedures as a method for ... is one of the first doctors to perform the treatment. Orthobiologics are substances ...
Breaking Medicine News(10 mins):